Chiasma to Report Fourth Quarter and Year End 2015 Financial Results on March 14

NEWTON, Mass., Feb. 26, 2016 -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced that it will be issuing its fourth quarter and year end 2015 financial results after the market’s close on Monday, March 14, 2016.

At 5:00 p.m. Eastern Time that day, Chiasma’s senior management team will host a conference call to discuss these results and other business updates. Investors can access a live and archived webcast of this call via the News & Investors section of the company’s website, www.ChiasmaPharma.com. Individuals may also participate in the live call via telephone by dialing (877) 317-6789 (domestic) or (412) 317-6789 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10080596.

About Chiasma

Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection.  The company’s lead product candidate is Mycapssa™ (octreotide) capsules, a new investigational drug for the orphan condition acromegaly, developed with Chiasma’s Transient Permeability Enhancer (TPE^®) technology to facilitate gastrointestinal absorption of unmodified drug into the bloodstream safely.  Mycapssa™ is a proposed tradename, and this new investigational drug has not been approved for use in any jurisdiction.  Using TPE^® technology, Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery.  TPE^® technology is potentially well suited for drugs with chronic indications, where frequent dosing is required and the need for an oral alternative is greatest.  Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Mycapssa™ and TPE^® are trademarks of Chiasma.

Additional information can be found at www.ChiasmaPharma.com.

Online Resources

Readers should note that Chiasma communicates with investors and the public using its website (www.ChiasmaPharma.com) and its investor relations website (http://ir.chiasmapharma.com), including but not limited to company disclosures; investor presentations and FAQs; Securities and Exchange Commission filings; press releases; public conference calls and webcasts. The information that the company posts on these websites could be deemed to be material information. As a result, Chiasma encourages investors, the media, and others interested to review the information that is posted there on a regular basis. The contents of the company’s website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Contacts:
Media:
Cammy Duong                                                                                   
MacDougall Biomedical Communications                                                    
(781) 591-3443                                                                       
[email protected]

Investors:
Jason Fredette
Chiasma, Inc.
(617) 928-5306
[email protected]